News from Friday, November 15, 2024
Articles
Overturning Chevron Doctrine Could Impact Medicare's Drug Selections For Price Negotiations
(11/14, Joshua P. Cohen, Forbes) comments “...Despite the election of Donald Trump as president along with Republican control of House and Senate, the popularity of prescription drug pricing provisions contained in the IRA makes it unlikely that the Medicare price negotiation component will be repealed. Still, in light of the Supreme Court decision, it's possible CMS may be challenged legally regarding its interpretation and operationalization of the IRA, particularly as it pertains to the selection of products subject to price negotiation.” Full
RFK Jr Vow to Purge FDA Sets up Collision With Big Pharma
(11/15, Reuters) reports "Robert F. Kennedy Jr. vowed to purge the U.S. Food and Drug Administration shortly before being chosen as President-elect Donald Trump's nominee for health secretary. Any changes he wants to make will come up against a pharmaceutical industry that pays much of the regulator's bills." Full
Louisiana's Bill Cassidy Named Next Chair of Senate Health Committee
(11/14, Zachary Brennan, Endpoints News) reports "Sen. Bill Cassidy (R-LA) will take over the Senate Health, Education, Labor, and Pensions Committee when the GOP gets control of the chamber in the next Congress, offering a change of pace on some priorities but a continued focus on issues like drug pricing." Subscription Required
UK: NICE May Be ‘Systematically Undervaluing’ Medicines for Severe Conditions, Says ABPI
(11/15, Katherine Price, The Pharmaceutical Journal) reports “...Commissioned and funded by the ABPI and published by the Office of Health Economics (OHE), the report — ‘Understanding societal preferences for priority by disease severity in England and Wales’, published on 14 November 2024 — suggests that NICE’s ‘severity modifier’, which is used to assess if a medicine is clinically and cost-effective, may be blocking innovative treatments that the public would like to see benefit NHS patients.” Full
Press Releases
NQF Board Welcomes 4 New Senior Execs From Leading Healthcare Consumer and Purchaser Organizations
(11/14, National Quality Forum Press Release) “...‘We are fortunate to have such a dedicated and highly respected group of leaders and visionaries representing all aspects of the healthcare ecosystem,’ said Dana Gelb Safran, ScD, President & CEO, NQF. ‘NQF’s board members are healthcare executives, advocates, and thought leaders who have been at the forefront of the national movement to systemically improve care quality at scale and for all people. We are excited to welcome four outstanding new members to our esteemed board. Their expert guidance will be invaluable to NQF as we work to reduce the measurement burden, and drive advances that make care measurably better, safer, more affordable, and more equitable.’” Full
Journals
Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)
Saakshi Khattri, et al.
November 9, 2024, Advances in Therapy
Budget Impact Analysis of Subcutaneous Infliximab (CT-P13 SC) for Treating Inflammatory Bowel Disease in Saudi Arabia: Analysis from Payer Perspective
Nimer S Alkhatib, et al.
November 12, 2024, PLOS One
Managing the Challenges of Paying for Gene Therapy: Strategies for Market Action and Policy Reform in the United States
Sharon Phares, Mark Trusheim, Sarah K Emond, and Steven D Pearson
November 14, 2024, Journal of Comparative Effectiveness Research
Reports
Understanding Societal Preferences for Priority by Disease Severity in England & Wales
November 2024